Advertisement
Advertisement
ADMA
ADMA Biologics, Inc.
10.38
USDSponsored
+0.68
+7.01%
Apr 13, 15:59 UTC -4
Closed
After-Market
10.43
+0.04
+0.43%
ADMA Earnings Reports
Positive Surprise Ratio
ADMA beat 19 of 41 last estimates.
46%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$145.55M
/$0.19
Implied change from Q4 25 (Revenue/ EPS)
+4.59%
/-5.00%
Implied change from Q1 25 (Revenue/ EPS)
+26.79%
/+72.73%
ADMA Biologics, Inc. earnings per share and revenue
On Feb 25, 2026, ADMA reported earnings of 0.20 USD per share (EPS) for Q4 25, beating the estimate of 0.18 USD, resulting in a 5.99% surprise. Revenue reached 139.16 million, compared to an expected 142.19 million, with a -2.13% difference. The market reacted with a -1.28% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of 0.19 USD, with revenue projected to reach 145.55 million USD, implying an decrease of -5.00% EPS, and increase of 4.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Fortress Biotech, Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.11
Actual
-$0.01
Surprise
-108.91%
Tvardi Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.65
Actual
-$0.78
Surprise
-18.33%
Tevogen Bio Holdings Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$2.04
Actual
-$1.45
Surprise
+28.92%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were ADMA Biologics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, ADMA Biologics, Inc. reported EPS of $0.20, beating estimates by 5.99%, and revenue of $139.16M, -2.13% below expectations.
How did the market react to ADMA Biologics, Inc.'s Q4 2025 earnings?
The stock price moved down -1.28%, changed from $17.93 before the earnings release to $17.70 the day after.
When is ADMA Biologics, Inc. expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for ADMA Biologics, Inc.'s next earnings report?
Based on 4
analysts, ADMA Biologics, Inc. is expected to report EPS of $0.19 and revenue of $145.55M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement